Market Overview

Acorda to Acquire Biotie Therapies for $25.60/ADS


Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it entered
into an agreement to acquire Biotie Therapies Corp. (NASDAQ: BITI) for €23.5680 per ADS in cash, or the equivalent of
$25.60 per ADS based on an exchange rate of 1.0864 U.S. dollars to
euros, which values Biotie at approximately $363 million.

Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a
receptor antagonist currently in Phase 3 development in
Parkinson's disease (PD). In a Phase 2b clinical trial, tozadenant
reduced average daily OFF time as an adjunct to treatment regimens
including levodopa/carbidopa.

Further expanding its Parkinson's pipeline, Acorda will also obtain
global rights to SYN120,

See full press release


Related Articles (ACOR + BITI)

View Comments and Join the Discussion!

Posted-In: M&A News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at